Solid Organ Transplantation: Principles and Pharmacotherapy

OPTN Goals: The Organ Procurement and Transplantation Network (OPTN), established in $1984$ , aims to increase transplantation rates, promote safety, and improve survival through national allocation policies.
Ethical Framework: Policies are guided by medical utility (maximizing net population benefit), medical justice (fairness), and respect for persons (honesty and autonomy).
Ischemic Time: The limit for kidneys is up to $36\,hours$ . Longer ischemic times correlate with tissue damage and decreased longevity.
Kidney Allocation System (2014): Prioritizes highly sensitized patients and those with the highest chance of post-transplant survival; wait time now begins at the start of dialysis.
Liver Allocation: Uses the Model for End-Stage Liver Disease (MELD) or PELD for pediatrics. Share 35 (implemented in $2013$ ) mandates regional offers to candidates with MELD scores higher than $35$ .
Heart and Lung Allocation:
- Heart allocation ( $2018$ update) prioritizes patients on ECMO or with significant decompensation over stable mechanical support.
- Lung allocation uses the Lung Allocation Score (LAS) (introduced in $2005$ ), which estimates wait-list mortality and post-transplant survival.

Definition: High-potency, short-course therapy used at the time of transplant to mitigate rejection risk or delay nephrotoxic maintenance drugs.
Risk Factors for Rejection: Includes younger age, African American race, prolonged ischemia time, and sensitization (previous human antigen exposure from pregnancy, blood transfusions, or prior transplants).
Pharmacological Agents:
- Glucocorticoids: High-dose IV ( $500\,mg$ to $1000\,mg$ ) for short duration.
- IL2-RA (Basiliximab/Simulect): Non-depleting; blocks IL-2 activation of CD25. Standard dose is $20\,mg$ on day $0$ and day $4$ .
- Antithymocyte Immune Globulin (Thymoglobulin): T-cell depleting polyclonal antibody; standard dose is $1.5\,mg/kg$ for $3$ to $5$ doses.
- Alemtuzumab: T-cell and B-cell depleting monoclonal antibody; standard dose is $30\,mg$ for $1$ dose.
Specific Trial Data: The INTAC study demonstrated that Alemtuzumab was superior to Basiliximab regarding biopsy-proven acute rejection (BPAR) in low-risk kidney recipients when attempting early corticosteroid withdrawal.

Traditional Regimens: Typically consist of a calcineurin inhibitor (CNI), an antimetabolite, and corticosteroids.
Calcineurin Inhibitors (CNIs):
- Include Tacrolimus and Cyclosporine. They require therapeutic drug monitoring due to narrow therapeutic indices and metabolic variability (e.g., $CYP3A5$ polymorphisms).
- Toxicities: Nephrotoxicity (affects $16.5\%$ of non-renal recipients), neurotoxicity, and metabolic complications (hyperglycemia).
Antimetabolites:
- Mycophenolate mofetil (CellCept): Dosed $500\,mg$ to $1500\,mg$ BID. Key toxicities include pancytopenias and GI distress.
- Azathioprine (Imuran): Dosed $1$ to $3\,mg/kg$ daily. Interaction with Allopurinol significantly increases toxicity risk.

Extended-Release Tacrolimus:
- Astagraf XL: Extended-release capsules.
- Envarsus XR (LCP-tacrolimus): Extended-release tablets with higher bioavailability ( $30\%$ ); requires approximately $30\%$ less dosage than IR-tacrolimus. Shown to reduce CNI-induced tremors in the STRATO study.
Belatacept (Nulojix):
- A second-generation CTLA-4-Ig fusion inhibitor that blocks CD80/86 on antigen-presenting cells.
- Clinical Findings: The BENEFIT trials showed improved GFR but higher early rejection rates compared to Cyclosporine.
- Boxed Warning: Increased risk of post-transplant lymphoproliferative disorder in EBV-mismatched (Donor +/Recipient -) patients; contraindicated in EBV-negative recipients.
mTOR Inhibitors (Sirolimus and Everolimus):
- Used to spare CNI-related nephrotoxicity. Everolimus has a shorter half-life ( $30\,hours$ ) compared to Sirolimus ( $62\,hours$ ).
- Adverse Effects: Wound-healing complications, hyperlipidemia, and proteinuria.

Acute Cellular Rejection (ACR): T-cell mediated; treated with high-dose steroids or depleting agents (ATG/Alemtuzumab) for steroid-resistant cases.
Antibody-Mediated Rejection (AMR): B-cell and plasma cell mediated. Requires histologic injury and evidence of donor-specific antibodies (DSAs) or $C4d$ deposition.
AMR Therapies:
- Plasmapheresis and IVIG: Traditional first-line therapy to remove and neutralize antibodies.
- Rituximab: Anti-CD20 monoclonal antibody; used to reduce the B-cell population.
- Proteasome Inhibitors (Bortezomib/Carfilzomib): Target active plasma cells. Associated with pancytopenias and neurotoxicity.
- Complement Inhibitors: Eculizumab (C5 inhibitor) and C1 esterase inhibitors target the final stages of cell lysis.

Pathophysiology: Multifactorial process involving immunologic (rejection) and nonimmunologic (CMV, ischemia, hypertension) mediators.
Prevention Strategies:
- Statins: Recommended for all adult heart transplant recipients regardless of cholesterol to prevent Cardiac Allograft Vasculopathy (CAV) ( $Class\,1, LOE\,A$ ).
- Azithromycin: Demonstrated utility in lung transplant recipients for preventing and treating Chronic Lung Allograft Dysfunction (CLAD), including Bronchiolitis Obliterans Syndrome (BOS).

Patient Care Scenario:

Question: Which induction protocol is best for minimizing corticosteroids while avoiding high rejection rates in the first post-transplant year?
Response: Alemtuzumab $30\,mg$ IV $\times\,1$ . The INTAC study showed Alemtuzumab's benefit over Basiliximab and ATG for corticosteroid avoidance, particularly in low-immunologic-risk cohorts.

Self-Assessment/Dialogue Summary:

Q: For which patient is wait time most dependent on provided therapies?
A: A $58-year-old$ woman with NYHA class IV heart failure (as heart allocation is based on therapies used for care).
Q: Patient L.H. (African American, $weight\,90\,kg$ , $SCr\,2.1\,mg/dL$ ) has $CYP3A5*1$ allele and headaches on Tacrolimus. What is the recommendation?
A: Change to LCP-tacrolimus ( $Envarsus\,XR$ ). Pharmacogenetic data suggest LCP-tacrolimus may provide more stable exposure in expressors.
Q: What is the most concerning issue for initiating Everolimus in a patient with multiple sternotomies and recent transplant?
A: Wound healing complications.
Q: Which patient benefits most from Azithromycin?
A: A lung transplant recipient to prevent progression of Chronic Lung Allograft Dysfunction (CLAD).